Sorrento, Under Shadow Of Chapter 11, Looks To Move BTK Inhibitor Into Phase III

 
• By Alaric DeArment

The biotech announced promising Phase IIa results for abivertinib in marginal zone lymphoma and is in talks with Chinese regulators about a Phase III trial.

Sorrento announced results from its Phase IIa trial of abivertinib in marginal zone lymphoma • Source: Shutterstock

More from Clinical Trials

More from R&D